Research on Cutaneous T-Cell Lymphoma Described by a Researcher at University of Cantabria (Kinases Inhibitors as New Therapeutic Opportunities in Cutaneous T-Cell Lymphoma).

Researchers at the University of Cantabria in Spain have conducted a study on cutaneous T-cell lymphoma (CTCL), a type of cancer characterized by high relapse rates and a lack of curative treatments. The study focuses on the potential of kinase inhibitors as therapeutic options for CTCL. The researchers highlight the JAK/STAT, MAPK/ERK, PI3K/Akt, and NF-kB signaling pathways as targets for inhibition. While JAK inhibitors show promise, further studies, particularly clinical trials, are needed to assess their benefits and potential adverse events, especially in patients with immunosuppression or underlying autoimmune diseases. [Extracted from the article]